Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrati
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Home
  2. Azioni
  3. Svezia
  4. Nasdaq Stockholm
  5. Active Biotech AB (publ)
  6. Notizie
  7. Altre lingue
    ACTI   SE0001137985

ACTIVE BIOTECH AB (PUBL)

(ACTI)
  Rapporto
Tempo differito Nasdaq Stockholm  -  16:32 30/11/2022
1.024 SEK   -0.58%
03/11Active Biotech AB (publ) riporta i risultati degli utili per il terzo trimestre e i nove mesi terminati il 30 settembre 2022
CI
17/08ACTIVE BIOTECH AB (PUBL) : RIGHTS ISSUE: 1 new share @ 1 SEK for 4 existing shares
FA
04/08Active Biotech AB (publ) riporta i risultati degli utili per il secondo trimestre e il semestre chiuso al 30 giugno 2022
CI
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su ACTIVE BIOTECH AB (PUBL)
03/11Preclinical data with tasquinimod in MDS to be presented at ASH 2022
03/11Active Biotech Q3 2022 - Approaching important milestones
03/11Active Biotech Interim Report Q3 2022
03/11Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended ..
24/10Active Biotech further strengthens the patent protection for laquinimod in eye disorder..
30/09Number of shares and votes in Active Biotech
07/09Active Biotech announces final outcome of the Company's rights issue
16/08Active Biotech publishes prospectus
04/08Active Biotech Q2'22 - Our comments
04/08Active Biotech announces a rights issue of approximately SEK 55 million
04/08Active Biotech Interim Report Q2 2022
04/08Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended ..
01/06Successful completion of the first stage of the phase IIa clinical trial of naptumomab ..
01/06Successful completion of the first stage of the phase IIa clinical trial of naptumomab ..
01/06Active Biotech AB Announces Successful Completion of the First Stage of the Phase Iia C..
19/05Annual General Meeting of Active Biotech AB
19/05Annual General Meeting of Active Biotech AB
18/05FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
18/05FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
18/05Active Biotech AB announces that Food and Drug Administration has granted tasquinimod O..
28/04Annual Report 2021 Active Biotech AB (publ)
26/04Active Biotech strengthens the patent protection for laquinimod in eye disorders
21/04Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2022
21/04Active Biotech Interim Report Q1 2022
20/04Active Biotech: Notice of annual general meeting of shareholders
31/03Number of shares and votes in Active Biotech
25/03Correction: Active Biotech Year End Report 2021
18/02Active Biotech - Advancing Three Active Projects
09/02Active Biotech: Year End Report 2021
09/02Active Biotech AB Reports Earnings Results for the Fourth Quarter and Full Year Ended D..
09/02Active Biotech enters into global patent license agreement with Oncode Institute for ta..
09/02Active Biotech Enters into Global Patent License Agreement with Oncode Institute for Ta..
07/02Active Biotech announces first patient dosed in the combination part of the phase Ib/II..
07/02Active Biotech Announces First Patient Dosed in the Combination Part of the Phase Ib/II..
04/01Active Biotech Appoints Erik Vahtola as Chief Medical Officer
04/01Active Biotech AB Appoints Erik Vahtola as Chief Medical Officer
2021Preclinical tasquinimod data presented at ASH 2021 available on Active Biotech's websit..
2021Active Biotech's nomination committee appointed
2021First subject dosed in phase I clinical study with eye-drop formulation of laquinimod  
2021Active Biotech AB Announces First Subject Dosed in Phase I Clinical Study with Eye-Drop..
2021Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotec..
2021Active Biotech's partner NeoTX to Present at the Society for Immunotherapy of Cancer (S..
2021New preclinical data on tasquinimod will be presented at the annual meeting of American..
2021Active Biotech Announces New Preclinical Data on tasquinimod Will Be Presented at the A..
2021211104_Interim Report Q3
2021Active Biotech Interim report January - September 2021  
2021Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended ..
2021Active Biotech: and NeoTX today announce that the first patient has been enrolled in the ..
2021Active Biotech and Neotx Announces That the First Patient Has Been Enrolled in the Phas..
2021Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combi..
2021Active Biotech Announces Tasquinimod Clinical Development in Multiple Myeloma Advances ..
2021Active Biotech: Company presentation
2021Active Biotech: Interim Report Jan-Jun 2021
2021Active Biotech Ab: Interim report January – June 2021
2021Active Biotech AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2..
2021Active Biotech's partner NeoTX will host KOL webinar on overcoming check point Inhibito..
2021Active Biotech provides status update of its clinical naptumomab project
2021Active Biotech AB Provides Status Update of its Clinical Naptumomab Project
2021Annual General Meeting of Active Biotech AB
2021Active Biotech: Company presentation May 2021
2021Annual Report 2020 Active Biotech AB (publ)
2021Active Biotech AB Interim report January – March 2021  
2021Active Biotech: NOTICE of ANNUAL GENERAL MEETING OF SHAREHOLDERS
2021Active Biotech and NeoTX Announce FDA Clearance of IND for Phase II Clinical Trial of N..
2021Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of N..
2021Number of shares and votes in Active Biotech
2021Number of shares and votes in Active Biotech
2021Active Biotech Year-end report January – December 2020  
2021Active biotech enters into a manufacturing agreement with famar health care services fo..
2021Active Biotech: rights issue heavily oversubscribed
2021Active Biotech: Adjustment of period for trading in subscription rights and interim share..
2021Active Biotech: publishes prospectus and certain new financial information included in th..
2020Active Biotech: Redeye initiates coverage of Active Biotech
2020Active Biotech Receive Milestone Payment From Neotx
2020Active Biotech Receive Milestone Payment from Neotx
2020Active Biotech's nomination committee appointed 
2020Report from extraordinary general meeting in Active Biotech and adjustment of previousl..
2020Active Biotech: announces the final terms of the rights issue
2020Active Biotech AB Appoints Elaine Sullivan as A Director
2020Correction To Previous Pressrelease: Active Biotech updates its clinical strategy and pro..
2020Correction To Previous Pressrelease: Active Biotech updates its clinical strategy and pro..
2020Correction To Previous Pressrelease: Active Biotech updates its clinical strategy and pro..
2020Active Biotech AB Announces Updates of its Fully Owned Projects Tasquinimod and Laquini..
2020Active Biotech: Updates its clinical strategy and projected milestones
2020Active Biotech: Updates its clinical strategy and projected milestones
2020Active biotech updates its clinical strategy and projected milestones
2020Active Biotech: Invitation to Active Biotech's virtual capital markets day
2020Active Biotech: Invitation to Active Biotech's virtual capital markets day
2020Invitation to Active Biotech's virtual capital markets day
2020Active Biotech: Notice of extraordinary general meeting in active biotech
2020Active Biotech: Notice of extraordinary general meeting in active biotech
2020Notice of extraordinary general meeting in active biotech
2020Active Biotech: announces rights issue
2020Active Biotech: Interim report January – September 2020
2020Active Biotech: Interim report January – September 2020
2020Active Biotech AB Publ Reports Earnings Results for the Third Quarter Ended September 3..
2020Active Biotech Interim report January – September 2020
2020Active Biotech Interim Report January - June 2020
2020Active Biotech announces first patient dosed in phase 1b/2a study of tasquinimod use in..
2020Active Biotech Announces First Patient Dosed in Phase 1B/2A Study of Tasquinimod Use in..
Prossimo evento su ACTIVE BIOTECH AB (PUBL)